-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since its discovery in 1921, insulin has been the main treatment for diabetes
Diabetes Metformin management consensus researchers want to verify, whether to start the GLP-1RA in routine clinical practice in T2D patients showed better heart vascular outcomes, and to this end a regional retrospective study
The research team visited a database in the Veneto region (Italy) to identify new patients with GLP-1RA or BI from 2014 to 2018
The results showed that among the background population of 5,242,201 citizens, 330,193 were determined to have diabetes
Comparison of cardiovascular results: According to the main intention-to-treat analysis (A) or the treated (B) analysis, the Forest chart shows the primary endpoint 3P-MACE ( major adverse cardiovascular events ) , its components, and other cardiovascular disease (CVD) outcomes Hazard ratio (HR) and 95% confidence interval (CI)
Comparison of cardiovascular results: According to the main intention-to-treat analysis (A) or the treated (B) analysis, the Forest chart shows the primary endpoint 3P-MACE ( major adverse cardiovascular events ) , its components, and other cardiovascular disease (CVD) outcomes Hazard ratio (HR) and 95% confidence interval (CI)
Independent baseline CVD of BI compared, the GLP-1RA patient 3P-MACE incidence significantly lower
Independent baseline CVD of BI compared, the GLP-1RA patient 3P-MACE incidence significantly lowerIn conclusion, compared with paired patients who initiated BI in the same medical system, T2D patients who initiated GLP-1RA had much better cardiovascular outcomes
Compared with paired patients who initiated BI in the same medical system, T2D patients who initiated GLP-1RA had much better cardiovascular outcomes
Longato, E.
, Di Camillo, B.
, Sparacino, G.
et al.
Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study.
Cardiovasc Diabetol 20,222 (2021).
https://doi.
org/10.
1186/s12933-021-01414-3 https://doi.
org/10.
1186/s12933-021-01414-3 in this message
